Interim PHINDER Analyses in Interstitial Lung Disease @checkrare
Interim PHINDER Analyses in Interstitial Lung Disease  @checkrare
Uploaded November 2026 | Updated November 2026, 3 hours ago
Parth Rali, MD, MBBS, FCCP, pulmonologist at Temple Health, discusses interim findings from the PHINDER study evaluating pulmonary hypertension (PH) screening strategies in patients with interstitial lung disease (ILD).

View the full interview at checkrare.com/phinder-analysis-highlights-the-need-for-earlier-pulmonary-hypertension-screening-in-interstitial-lung-disease
Interim PHINDER Analyses in Interstitial Lung DiseaseCh 3: VALIANT Results on the Longer-Term Impact of EmpaveliFDA Approves New Therapies for MPS IIIA and SMA | The CheckRare Brief Ep 8Fabry Disease: Patients Real-World Problems and How to Manage ThemA Family’s Journey with Prader-Willi SyndromeCongenital Hyperinsulinism Diagnosis and ManagementResults from the CALIBRATE Clinical Trial in Patients With Autosomal Dominant Hypocalcemia Type 1Decoding Delays, Connecting the Care: The Challenge of Diagnosing Rare Endocrine DisordersRare Endocrine Exchange: Diagnosing Rare Endocrine DisordersAntiphospholipid Syndrome and PregnantASCO 2026: MajesTEC-9 Clinical Trial ResultsTaletrectinib for ROS1-Positive Non-Small Cell Lung Cancer
CheckRare |

Interim PHINDER Analyses in Interstitial Lung Disease

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER